Amari L, Tomasini P, Dantony E, Rousseau-Bussac G, et al. Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC Lung Cancer 2024;193:107843.
PMID: 38830303